Tag: accentuates
OSE Immunotherapeutics accentuates its losses in 2023
(AOF) – OSE Immunotherapeutics announces a cash position of 18.7 million euros as of December 31, 2023, to which will be added $48 million expected under the agreement with AbbVie…
Mastrad accentuates its losses in the first half
(AOF) – A pioneer in foodtech specializing in temperature measurement, Mastrad widens its losses in the first half of the year, which amounted to 1.42 million euros compared to 1.21…
Mastrad accentuates its losses in the first half – 10/30/2023 at 6:28 p.m.
(AOF) – A pioneer in foodtech specializing in temperature measurement, Mastrad widens its losses in the first half of the year, which amounted to 1.42 million euros compared to 1.21…
Toosla accentuates its losses in the first half of 2023
(AOF) – In the first half of 2023, Toosla records a net loss of 3.6 million euros compared to 1.12 million a year ago, for a turnover increased from 2.99…
Toosla accentuates its losses in the first half of 2023 – 10/11/2023 at 6:15 p.m.
(AOF) – In the first half of 2023, Toosla records a net loss of 3.6 million euros compared to 1.12 million a year ago, for a turnover increased from 2.99…
Orpea accentuates its losses in the first half of 2023
(AOF) – Orpea publishes consolidated turnover for the first half of 2023, up +10.7% compared to 2022. The group posts a net loss of 371 million euros for this half-year…
Orpea accentuates its losses in the first half of 2023 – 10/11/2023 at 6:39 p.m.
(AOF) – Orpea publishes consolidated turnover for the first half of 2023, up +10.7% compared to 2022. The group posts a net loss of 371 million euros for this half-year…
OSE Immunotherapeutics accentuates its losses in the first half of 2023
(AOF) – OSE Immunotherapeutics announces that as of June 30, 2023, its available cash flow amounted to 15 million euros, ensuring financial visibility until the fourth quarter of 2024. In…
OSE Immunotherapeutics accentuates its losses in the first half of 2023 – 09/27/2023 at 6:18 p.m.
(AOF) – OSE Immunotherapeutics announces that as of June 30, 2023, its available cash flow amounted to 15 million euros, ensuring financial visibility until the fourth quarter of 2024. In…
Abivax accentuates its losses in the first half
(AOF) – Abivax announces that its cash flow as of June 30, 2023 amounts to 114.4 million euros compared to 27.0 million euros at the end of 2022. The biotech…
Abivax accentuates its losses in the first half – 09/21/2023 at 6:26 p.m.
(AOF) – Abivax announces that its cash flow as of June 30, 2023 amounts to 114.4 million euros compared to 27.0 million euros at the end of 2022. The biotech…
In old-age insurance, the pension reform accentuates the “malaise” of staff
The pressure weighing on them has just increased even though they already found it to be high. With the entry into force – from 1er September – of the pension…